- Home
- Publications
- Publication Search
- Publication Details
Title
IMWG consensus on risk stratification in multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 2, Pages 269-277
Publisher
Springer Nature
Online
2013-08-26
DOI
10.1038/leu.2013.247
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
- (2013) Tae-Hoon Chung et al. PLoS One
- Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple Myeloma
- (2012) Nicolaus Kröger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
- (2012) S. Kumar et al. BLOOD
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- (2012) J. B. Egan et al. BLOOD
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
- (2012) S. Waheed et al. HAEMATOLOGICA
- Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma
- (2012) J. Hillengass et al. HAEMATOLOGICA
- Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
- (2012) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
- (2012) H Avet-Loiseau et al. LEUKEMIA
- A gene expression signature for high-risk multiple myeloma
- (2012) R Kuiper et al. LEUKEMIA
- High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
- (2011) B. Paiva et al. BLOOD
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
- (2011) A. Palumbo et al. BLOOD
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
- (2011) N. C. Munshi et al. BLOOD
- Approach to the treatment of multiple myeloma: a clash of philosophies
- (2011) S. V. Rajkumar et al. BLOOD
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
- (2011) G. J. Morgan et al. BLOOD
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
- (2011) F. Gay et al. BLOOD
- Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
- (2011) E. Zamagni et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Gene Expression Profiling in Multiple Myeloma--Reporting of Entities, Risk, and Targets in Clinical Routine
- (2011) T. Meissner et al. CLINICAL CANCER RESEARCH
- Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
- (2011) K. D. Boyd et al. CLINICAL CANCER RESEARCH
- A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
- (2011) K D Boyd et al. LEUKEMIA
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Treatment of multiple myeloma
- (2011) S. Vincent Rajkumar Nature Reviews Clinical Oncology
- Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
- (2010) H. Avet-Loiseau et al. BLOOD
- Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
- (2010) P. Moreau et al. BLOOD
- Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome
- (2010) N. J. Dickens et al. CLINICAL CANCER RESEARCH
- Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
- (2010) K. Neben et al. HAEMATOLOGICA
- A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
- (2010) J. Moreaux et al. HAEMATOLOGICA
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
- (2010) D. Hose et al. HAEMATOLOGICA
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
- (2010) Heinz Ludwig et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
- (2010) Marco Ladetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma
- (2010) W J Chng et al. LEUKEMIA
- The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
- (2010) NATURE BIOTECHNOLOGY
- How I treat multiple myeloma in younger patients
- (2009) A. K. Stewart et al. BLOOD
- Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
- (2009) A. Hoering et al. BLOOD
- TP53deletion is not an adverse feature in multiple myeloma treated with total therapy 3
- (2009) John D. Shaughnessy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
- (2009) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
- (2009) Shaji K. Kumar et al. MAYO CLINIC PROCEEDINGS
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- Impact of early relapse after auto-SCT for multiple myeloma
- (2008) S Kumar et al. BONE MARROW TRANSPLANTATION
- Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
- (2008) Bart Barlogie et al. CANCER
- Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
- (2008) Olivier Decaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
- (2008) Juan José Lahuerta et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started